Immunic to Participate in Industry and Scientific Conferences in June

Rhea-AI Summary

Immunic (Nasdaq: IMUX), a biotechnology company focused on developing oral therapies for chronic inflammatory and autoimmune diseases, announced its participation in key industry and scientific conferences in June 2024. The company will present at the BIO International Convention in San Diego, California, from June 3-6, with Jessica Breu, VP of Investor Relations and Communications, presenting on June 4 at 11:00 am PDT. Immunic's management will engage in partnering activities at this event. Additionally, Werner Gladdines, VP of Program Management and Clinical Development Operations, will join a panel discussion at the Pharmaceutical Contract Management Group (PCMG) Assembly in Den Haag, The Netherlands, from June 5-7. His panel, 'Spin the Wheel of Collaboration!', is scheduled for June 6 at 12:05 pm CEST.

Positive

• Immunic's participation in major industry conferences can boost visibility and investor interest.
• Presentation at BIO International Convention allows for business development and networking opportunities.
• Archived replay of the presentation increases accessibility for stakeholders unable to attend live.
• Involvement in a panel at PCMG Assembly highlights Immunic's expertise in clinical development.

Negative

• No direct update on clinical trial progress or new data shared in the press release.
• Details on financial impact or expected outcomes from conference participation are lacking.
• Potential dilution of focus by participating in multiple events within a short timeframe.

NEW YORK, May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and scientific conferences in June:

• June 3-6: BIO International Convention 2024. Jessica Breu, Vice President Investor Relations and Communications of Immunic, will present a company overview on Tuesday, June 4, 2024, at 11:00 am PDT in Theater 1, at this conference in San Diego, California. The presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations. An archived replay will be available after the conference.
  
  Members of Immunic's management, business development and investor relations teams will participate in partnering activities. To schedule a meeting, please use the BIO International Convention partnering portal.
  
  
• June 5-7: Pharmaceutical Contract Management Group (PCMG) Assembly 2024. Werner Gladdines, Vice President, Program Management & Clinical Development Operations of Immunic, will participate in a panel discussion at this assembly in Den Haag, The Netherlands.
  • Panel: Spin the Wheel of Collaboration!
  • Date: Thursday, June 6, 2024
  • Time: 12:05 pm CEST

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, for which it is currently in preparations for a phase 2 clinical trial. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in industry and scientific conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 22, 2024, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information 

Immunic, Inc. 
Jessica Breu 
Vice President Investor Relations and Communications
+49 89 2080 477 09 
jessica.breu@imux.com 

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com 

US Media Contact
KOGS Communication
Edna Kaplan
+1 617 974 8659
kaplan@kogspr.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-industry-and-scientific-conferences-in-june-302156368.html

SOURCE Immunic, Inc.

FAQ

What events will Immunic participate in June 2024?

Immunic will participate in the BIO International Convention from June 3-6 and the PCMG Assembly from June 5-7.

When is Immunic's presentation at the BIO International Convention?

Immunic's presentation at the BIO International Convention is scheduled for June 4, 2024, at 11:00 am PDT.

Who will represent Immunic at the BIO International Convention?

Jessica Breu, Vice President of Investor Relations and Communications, will represent Immunic at the BIO International Convention.

How can I access Immunic's presentation at the BIO International Convention?

The presentation will be accessible on Immunic's website in the 'Events and Presentations' section.

What is the focus of Werner Gladdines' panel at the PCMG Assembly?

Werner Gladdines will participate in the 'Spin the Wheel of Collaboration!' panel at the PCMG Assembly.

When is the 'Spin the Wheel of Collaboration!' panel discussion at the PCMG Assembly?

The 'Spin the Wheel of Collaboration!' panel discussion is scheduled for June 6, 2024, at 12:05 pm CEST.